Nakajima Medical Clinic, Kobe, Japan.
Division of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine, Kobe, Japan
In Vivo. 2022 Mar-Apr;36(2):949-953. doi: 10.21873/invivo.12785.
BACKGROUND/AIM: Although the usefulness of inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) in cough-variant asthma and cough-predominant asthma has been reported, there is no consensus on its starting dose. The aim of this study is to find the optimal dose of ICS/LABA for cough-variant asthma and cough-predominant asthma.
We analysed 112 patients who visited our clinic from January 2009 to December 2012 with the chief complaint of cough that had continued for more than 3 weeks. Cough-variant asthma (n=30) and cough-predominant asthma (n=7) were treated with ICS/LABA.
There was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma and cough-predominant asthma between medium and high doses (14.3% versus 10.9%, respectively) (p=0.192). Moreover, there was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma between medium and high doses (13.2% versus 11.5%, respectively) (p=0.433).
The medium starting dose of ICS/LABA is sufficient for treating cough-variant asthma.
背景/目的：虽然吸入性皮质类固醇和长效β2 受体激动剂（ICS/LABA）在咳嗽变异性哮喘和以咳嗽为主要表现的哮喘中的有效性已得到报道，但对于其起始剂量尚无共识。本研究旨在确定 ICS/LABA 治疗咳嗽变异性哮喘和以咳嗽为主要表现的哮喘的最佳剂量。
我们分析了 2009 年 1 月至 2012 年 12 月期间因持续咳嗽超过 3 周而就诊于我们诊所的 112 例患者。咳嗽变异性哮喘（n=30）和以咳嗽为主要表现的哮喘（n=7）采用 ICS/LABA 治疗。
在咳嗽变异性哮喘和以咳嗽为主要表现的哮喘中，ICS/LABA 起始剂量的中剂量和高剂量组之间的咳嗽持续时间无显著差异（分别为 14.3%和 10.9%）（p=0.192）。此外，在咳嗽变异性哮喘中，ICS/LABA 起始剂量的中剂量和高剂量组之间的咳嗽持续时间也无显著差异（分别为 13.2%和 11.5%）（p=0.433）。
ICS/LABA 的起始中剂量足以治疗咳嗽变异性哮喘。
